Imugene (ASX: IMU) — Perfil da empresa, notícias e dados financeiros
Imugene is a clinical-stage immuno-oncology company developing T-cell receptor therapies and oncolytic virotherapies for cancer treatment.
Imugene
Imugene is a clinical-stage immuno-oncology biotechnology company focused on developing novel cancer therapies designed to harness the immune system to treat B-cell malignancies and solid tumors. The company's platform includes allogeneic chimeric antigen receptor T-cell therapies, oncolytic viruses, and cancer immunotherapies. Its clinical pipeline features off-the-shelf cellular therapeutics such as azercabtagene zapreleucel, targeting CD19-expressing blood cancers, along with proprietary oncolytic virus technologies like CF33 and B-cell immunotherapy platforms. Imugene conducts clinical trials across novel targets to provide therapeutic options for patients with advanced or refractory cancers.
Resumo
Operações
Produtos e/ou serviços de Imugene
- Allogeneic Cell Therapies: Off-the-shelf cellular immunotherapy programs centered on azercabtagene zapreleucel targeting CD19 in Phase 1b clinical trials for B-cell malignancies and non-Hodgkin lymphoma to evaluate safety and clinical efficacy in patients.
- Oncolytic Virus Therapies: Engineered chimeric poxvirus platforms featuring VAXINIA and CHECKvacc constructs designed to selectively infect, replicate within, and lyse tumor cells while activating systematic antitumor immune responses across multiple solid tumor indications.
- B-Cell Immunotherapies: Active immunotherapeutic platforms including HER-Vaxx and PD1-Vaxx vaccine candidates engineered to stimulate the host immune system to generate polyclonal antibodies targeting specific cancer antigens such as HER2 and PD-1 pathways.
- Combination Tumor Platforms: Oncolytic virus technologies engineered to express CD19 targets on solid tumor cells, enabling CD19-directed CAR T cell therapies and targeted therapeutics to recognize and destroy previously untargetable solid tumor masses.
- Clinical Development Operations: Clinical trial management conducting Phase 1 and Phase 2 human trials across medical centers in Australia and North America to evaluate therapeutic safety, dosage escalation, and therapeutic efficacy across novel targets.
- Biopharmaceutical Licensing: Strategic licensing and collaborative research agreements for proprietary cell therapy and oncolytic virus platforms, supporting pre-clinical asset discovery, technology transfer, and commercialization pathways across global biopharmaceutical markets.
equipe executiva do Imugene
- Paul Edward-Alexander HopperExecutive Chairman
Últimas notícias sobre a Imugene
Imugene reports 71% response rate in trial
AustraliaImugene CEO steps down after 11 years
AustraliaImugene completes $11.1M share placement
AustraliaImugene records second complete clinical response
AustraliaImugene reports first complete trial patient response
AustraliaThe startup tax workaround quietly reshaping local venture capital networks
Australia
Comunicados recentes
O que a Imugene (IMU) comunicou ao mercado, do mais recente para o mais antigo.
- Notice of Annual General Meeting/Proxy Form
- Dr John Le Gall appointed Chief Medical Officer
- azer-cel BTKi Cohort Reports new Complete & Partial ResponseFato relevante
- Change of Director's Interest Notice - JD
Principais indicadores financeiros
Resultados divulgados pela Imugene, em AUD.
- Cap. de mercado
- 19,9 mi
- Receita (TTM)
- 2,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -75 mi | -105,3 mi | |
| 4,4 mi | -70,9 mi | -69 mi | |
| 5 mi | -140,9 mi | -149,7 mi | |
| 11,8 mi | -51,3 mi | -37,9 mi |